An open-label, multiple-dose, two-treatment period study to evaluate the effect of oral BAF312 on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female volunteers.

Published: 16-02-2012
Last updated: 26-04-2024

Objectives:- To investigate whether BAF312 administered daily at a dose of 4 mg can affect exposure (Cmax,ss and/or AUCtau) to a daily administered monophasic oral contraceptive (OC) regimen containing 30 µg of ethinylestradiol (EE) and 150 µg of...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Autoimmune disorders
Study type	Interventional

Summary

ID

NL-OMON37415

Source
ToetsingOnline

Brief title
CBAF312A2121 (CS0175)

Condition

- Autoimmune disorders

Synonym
MS, Multiple Sclerosis

Research involving
Human

Sponsors and support

Primary sponsor: Novartis
Source(s) of monetary or material Support: Novartis

Intervention

Keyword: BAF312, female, pharmacodynamics, pharmacokinetics

Outcome measures

Primary outcome

To investigate whether BAF312 administered daily at a dose of 4 mg can affect exposure (Cmax and AUC) to a daily administered monophasic oral contraceptive (OC) regimen containing 30 µg of ethinylestradiol (EE) and 150 µg of levonorgestrel (LVG).

Secondary outcome

- To assess the effect of oral BAF312 (4 mg q.d.) on the pharmacodynamics of a monophasic OC determined by Hoogland score, FSH, LH, estradiol, progesterone,SHBG concentrations and ovarian follicle size
- To assess the safety and tolerability of oral BAF312 (4 mg q.d.) in co-administration with a monophasic OC,
- To assess the PK profile of oral BAF312 (4 mg q.d.) when combined with a daily administered monophasic oral contraceptive (OC) regimen containing 30 µg of EE and 150 µg of LVG.

Study description

Background summary

This study will investigate the potential effect of BAF312 on the pharmacokinetics and pharmacodynamics of combined monophasic ethinylestradiol (EE) and levonorgestrel (LVG), the components of a commonly prescribed, low dose, oral contraceptive (OC) in
order to provide labeling information for women of child-bearing potential.

Study objective

Objectives:
- To investigate whether BAF312 administered daily at a dose of 4 mg can affect exposure (Cmax,ss and/or AUCtau) to a daily administered monophasic oral contraceptive (OC) regimen containing 30 µg of ethinylestradiol (EE) and 150 µg of levonorgestrel (LVG).
- To assess the effect of oral BAF312 (4 mg q.d.) on the pharmacodynamics of a monophasic OC determined by Hoogland score, FSH, LH, estradiol, progesterone, SHBG concentrations and ovarian follicle size.

Study design

The study employs an open-label, single center, single sequence, two- treatment period design, in 24 healthy female subjects. The subjects will be exposed sequentially to OC alone in period 1; BAF312 will be titrated up to 2 mg in the last 6 days of period 1, then OC will be co-administered with BAF312 4 mg q.d in period 2.

Intervention

The study will start with a screening visit. During the screening visit standard medical assessments including safety laboratory tests (blood draw, urine collection), an alcohol breath test, urine drug screen, a physical examination, ECG and a vital signs measurement will be performed. In addition standard gynecological test will be performed.

After the subject passes all above mentioned tests, the subject will be enrolled in the synchronization phase.

During the confinement period the subjects will receive the study medication, will be asked on a regular basis for possible side effects, blood will be drawn for safety and PK/PD measurements and the vital signs / ECG will be checked regularly. During the outpatient periods, the subject will return in regular intervals. During these visits the subjects will be asked for possible side effects, blood will be drawn for safety and PK/PD
measurements, the vital signs/ECG will be checked.

Finally a follow-up examination will be performed. During this visit the subjects will be asked for possible side effects, blood will be drawn for safety, the vital signs/ECG will be checked and a physical examination will be conducted.

Study burden and risks

The test medication has been previously tested in over 450 healthy human subjects and over 300 patients of Multiple Sclerosis and polymyositis/dermatomyositis. The test medication was generally well tolerated. A number of side-effects, possibly linked to use of the test medication, were reported. These side-effects included, in the majority of cases, nervous system disorders (headache and dizziness), gastro intestinal disorders (nausea), cardiac disorders (changes in heart rate and heart rhythm)) , alteration in liver function, decrease in lymphocytes (white blood cells) count, increased risk of infections and swelling of the retina (swelling of the retina was seen in one case in a MS patient in phase II trial).

The OC will contain EE and LVG. The doses of EE (30 µg) and LVG (150 µg) are widely used in clinical practice. The most common side effects reported for oral OCs are: nausea, abdominal pain, increased weight, headache, depressed or altered mood, breast pain or tenderness.

The blood collection procedures may cause discomfort or bruising. Occasionally, fainting or an infection at the blood sampling site can occur.

Contacts

Public
Novartis

Postfach
CH-4002 Basel
NL
Scientific
Novartis

Postfach
CH-4002 Basel
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Woman between the ages of 18 and 40 years and a non-smoker. BMI between 18 and 30, with a minimum weight of 50 kg.

Exclusion criteria

Clinical significant abnormalities at medical research

Study design

Design

Study type: Interventional

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	28-02-2012
Enrollment:	24

Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	BAF312
Generic name:	BAF312

Ethics review

Approved WMO Date:	16-02-2012
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	27-02-2012
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2011-006043-30-NL
CCMO	NL39811.056.12